All In Biotech

Drug Trial Radar · NCT06513104

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

Investigation of the Effect of NNC0519-0130 on the Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) and Gastric Emptying in Healthy Postmenopausal Females

Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Jul 18, 2024

Primary completion

Sep 10, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to investigate if NNC0519-0130 affects the blood levels of a birth control pill that contains the two hormones ethinylestradiol and levonorgestrel. The study will also look into if NNC0519-0130 affects how fast stomach is emptied. Participants will get the new study medicine NNC0519-0130 and will also get birth control pills and paracetamol. The study will last for about 35 weeks.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • NNC0519-0130Drug

    NNC0519-0130 will be administered subcutaneously.

  • Levonorgestrel + EthinylestradiolDrug

    Levonorgestrel + Ethinylestradiol will be administered orally.

  • ParacetamolDrug

    Paracetamol will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady stateTime frame: Day 8
  2. Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady stateTime frame: Day 188
  3. Area under the levonorgestrel plasma concentration time curve during a dosing interval at steady stateTime frame: Day 8
  4. Area under the levonorgestrel plasma concentration time curveduring a dosing interval at steady stateTime frame: Day 188

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International GmbH

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.